Zepp Health (ZEPP) CTO Meihui Fan Buys 520,000 Shares

Meihui Fan, the Chief Technology Officer of ZEPP, made a significant move by buying 520,000 shares of the company on June 26, 2026. This insider transaction highlights her confidence in the company's prospects.

Other Institutional Activity in ZEPP

Several institutional investors have also adjusted their positions in ZEPP. FIL LTD increased its holdings by 91,596 shares, bringing its total to 717,352 shares worth about $8.57 million. Morgan Stanley added 97,397 shares, ending with 707,691 shares valued at $8.46 million. Meanwhile, Point72 Asset Management slightly reduced its holdings by 294 shares, maintaining a total of 577,676 shares worth approximately $6.90 million. Millennium Management trimmed its position by 24,322 shares, now holding 342,504 shares valued at $4.09 million. Price T Rowe Associates increased its stake by 15,946 shares to a total of 311,913 shares, worth about $3.73 million.

Zepp Health Corporation Stock Up 9.5%

Shares of ZEPP traded near $4.73 on Tuesday. The company has seen various institutional activities reflecting mixed sentiments. Despite these fluctuations, ZEPP continues to attract attention from both insiders and institutional investors.

Insider Buying and Selling at Zepp Health Corporation

On June 26, 2026, ZEPP's Chief Technology Officer, Meihui Fan, purchased 520,000 shares. On the same day, the Chief Financial Officer, Deng Cheng, was also active in the market. Cheng bought 22,875 shares and sold 9,836 shares at an average price of $4.61. Earlier, on April 1, 2026, Cheng acquired 366,000 shares.

Analysts Set New Price Targets

Citi maintained its buy rating on ZEPP, with a price target of $3.10 as of August 21, 2023. This reflects continued optimism from analysts regarding the company's future performance.

Bottom Line

The recent insider buying by Meihui Fan indicates strong confidence in ZEPP's future. Institutional investors are also actively adjusting their positions, suggesting varied views on the company's potential. Analysts, like those at Citi, remain optimistic, maintaining a buy rating. As always, it's important to remember that these filings are backward-looking and may not reflect the current situation.